Nixon, A. B., Sibley, A., Hatch, A. J., Liu, Y., Jiang, C., Mulkey, F., … Hurwitz, H. (2016). Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance). In Journal of Clinical Oncology (Vol. 34, pp. 3597–3597). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.3597

Nixon, Andrew B., Alexander Sibley, Ace Joseph Hatch, Yingmiao Liu, Chen Jiang, Flora Mulkey, Mark D. Starr, et al. “Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).” In Journal of Clinical Oncology, 34:3597–3597. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3597.

Nixon AB, Sibley A, Hatch AJ, Liu Y, Jiang C, Mulkey F, et al. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3597–3597.

Nixon, Andrew B., et al. “Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 3597–3597. Crossref, doi:10.1200/jco.2016.34.15_suppl.3597.

Nixon AB, Sibley A, Hatch AJ, Liu Y, Jiang C, Mulkey F, Starr MD, Brady JC, Niedzwiecki D, Innocenti F, Venook AP, Hochster HS, Lenz H-J, O’Neil BH, Owzar K, Hurwitz H. Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3597–3597.